LINTONPHARM
1.12.2021 14:02:14 CET | Business Wire | Press release
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847 ), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”
A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control [1] . Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.
Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC [2][3] . Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG [3] .
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.
Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (clinicaltrials.gov: NCT04222114 ).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. For more information, please visit www.lintonpharm.com .
[1]. Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunology, Immunotherapy. http://doi.org/10.1007/s00262-021-02930-7 |
[2]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/ |
[3]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005307/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mary Kay’s Pink Changing Lives® Program Turns Purpose Into Measurable Impact for Women Around the World6.8.2026 14:05:00 CEST | Press release
More than 4 million women have benefited through nonprofit organizations supported by the program since its launch. Mary Kay Inc., a global advocate for women’s empowerment, proudly reaffirms its commitment to enriching women’s lives worldwide through its signature Pink Changing Lives® Program – a multi-faceted global initiative that blends purpose-driven giving with cause-marketing to create meaningful, measurable impact across communities. Since 1996, the program has provided over $230 million in monetary and product donations to nonprofit organizations empowering women, transforming women’s health and safety, and protecting our natural resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806671194/en/ Mary Kay China supports the Hope for Pearl Program, providing financial assistance to girls from economically disadvantaged areas to receive a life-changing education, opening doors to new possibilities and bright fu
Perpetuals Reports 380% Hypothetical Return in Backtest of AI Engine Powering Risk-Free Trading Platform ‘UpsideOnly’6.8.2026 14:00:00 CEST | Press release
Results provide early evidence that BayesShield can identify potentially profitable trading signals by finding repeatable skill in trader activity375-day backtest using Perpetuals’s production code generated a hypothetical 380% non-compounded return, a period in which Bitcoin fell 40.2%The strategy achieved a return-to-drawdown ratio of 4.4, a measure comparing its overall return with the largest decline it experienced during the test Perpetuals.com Ltd (Nasdaq: PDC) today announced backtest results for version two of BayesShield, its patent-pending AI engine developed for UpsideOnly. UpsideOnly is a risk-free paper trading platform where users simulate trades using virtual money across global equity, commodity, foreign exchange and crypto markets. The platform is powered by BayesShield, an AI model that uses machine learning to identify consistently successful traders. It generates automated signals when enough qualified traders independently take the same position at approximately th
Adtran launches Mosaic One Fabric, empowering operators to build custom AI agents and workflows6.8.2026 14:00:00 CEST | Press release
News summary: Operators need the autonomy and tools to create AI agents and workflows that address their own business priorities Adtran’s Mosaic One Fabric enables operators to create, govern and scale AI agents without vendor lock-in Open foundation gives operators more control over their data, agents and token economics while accelerating innovation Adtran today launched Mosaic One Fabric, an expansion of its Mosaic One software platform, enabling operators to create AI agents and workflows around their own operational priorities. Rather than being limited to predefined agents, fixed use cases or vendor-controlled ecosystems, operators can build and scale AI on their own terms using the data, tokens and models that best fit their business, with the token economics visible and under their control. Mosaic One Fabric brings together trusted operational intelligence, vendor-agnostic AI integration and the guardrails needed to run AI safely across the network. By combining Adtran capabili
NetApp Acquires JetStream Software to Advance Cyber Resilience and Data Protection for the AI Era6.8.2026 14:00:00 CEST | Press release
Acquisition strengthens NetApp’s portfolio with recovery and mobility capabilities that help organizations reduce risk and accelerate transformation NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced it has acquired JetStream Software, a leader in VMware disaster recovery and migration. Enterprise customers continue to rely on VMware for many of their most critical applications. As organizations evaluate cloud adoption, they often seek ways to transition workloads while minimizing cost, complexity, and operational disruption. For many, disaster recovery serves as a practical first step, with production workloads migrating over time as cloud strategies mature. “Data has become the foundation for business growth, AI innovation, and operational continuity,” said George Kurian, Chief Executive Officer at NetApp. “As customers look to unlock greater value from their data while strengthening protection against disruption, bringing JetStream into NetApp expan
Omilia Secures $67 Million in Series B Funding to Accelerate Global Expansion of Its Agentic Self-Learning CX Platform for Large Enterprises6.8.2026 14:00:00 CEST | Press release
ARR surpasses $60 million, growth of more than 10x since the company's Series ANamed a Leader in The Forrester Wave™ Conversational AI Platforms for Customer Service, Q2 2026Investment led by transatlantic software & AI specialist Expedition Growth Capital Omilia, the Self-Learning Agentic CX company trusted by many of the world's largest enterprises, today announced a $67 million Series B funding round led by transatlantic software & AI specialist, Expedition Growth Capital. Omilia builds Agentic CX for the world's largest and most demanding enterprises – organizations often in regulated industries such as banking, insurance and healthcare, where security, scalability and cost predictability are non-negotiable. Its customers include Capital One, Discover, RBC, Taco Bell, DWP and PSEG. The company's voice-first AI platform, honed over more than 200 enterprise deployments, is built entirely on its own proprietary agentic Voice AI technology, and supports the most stringent enterprise se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom